Cell therapy (CAR-T) · Kills target cells, directed at CD70 · developed by Adicet Therapeutics
ADI-270 is an allogeneic gamma delta T-cell therapy engineered with a CAR targeting CD70 and a dominant negative TGF-beta receptor II. It recognizes and kills CD70-expressing tumor cells while resisting TGF-beta-mediated immunosuppression in the tumor microenvironment. It is being studied in clear cell renal cell carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06480565 | Phase 1/2 | Clear Cell Renal Cell Carcinoma | Active not recruiting | ACET |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Clear Cell Renal Cell Carcinoma
See ACET's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ACET catalysts and pipeline →